- Published at
- by gurufocus.com
positive
positive
News for Stoke Therapeutics, Inc. (STOK)
- Published at
- by seekingalpha.com
positivepositiveBiogen and Stoke Therapeutics collaborates to develop Dravet syndrome treatment globally (BIIB:NASDAQ)
Biogen & Stoke team up to advance zorevunersen for Dravet syndrome globally- Published at
- by financialpost.com
positivepositiveBiogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and N
Stoke retains exclusive rights for zorevunersen in the United States, Canada, and Mexico; Biogen receives exclusive rest of world commercialization rights- Published at
- by gurufocus.com
neutralneutralGeneDx Reports Fourth Quarter and Full Year 2024 Financial Results and Issues Guidance for Full Year 2025
GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the fou- Published at
- by seekingalpha.com
positivepositiveStoke Therapeutics Stock: A Pivotal Moment For This RNA Pioneer (NASDAQ:STOK)
Discover Stoke Therapeutics' innovative RNA-based treatments like zorevunersen for Dravet syndrome, with a promising pipeline and market-expanding potential.- Published at
- by gurufocus.com
positivepositiveLynx1 Capital Management LP Increases Stake in Allogene Therapeutics Inc
On December 31, 2024, Lynx1 Capital Management LP (Trades, Portfolio) made a significant move by acquiring an additional 4,672,349 shares of Allogene Therapeuti- Published at
- by gurufocus.com
positivepositiveLynx1 Capital Management LP Acquires Significant Stake in Precision BioSciences Inc
Overview of the Recent Transaction On December 31, 2024, Lynx1 Capital Management LP (Trades, Portfolio) executed a notable transaction by acquiring 766,051 sha- Published at
- by gurufocus.com
positivepositiveRTW INVESTMENTS, LP Expands Stake in Stoke Therapeutics Inc
Significant Transaction in Stoke Therapeutics Inc On December 31, 2024, RTW INVESTMENTS, LP (Trades, Portfolio) executed a notable transaction by acquiring an a- Published at
- by zacks.com
positivepositiveStrength Seen in Stoke Therapeutics (STOK): Can Its 9.4% Jump Turn into More Strength?
Stoke Therapeutics (STOK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.- Published at
- by zacks.com
positivepositiveIs it a Good Idea to Invest in Stoke Therapeutics Stock Now?
Here, we discuss some reasons why investing in STOK now may turn out to be a prudent move.- Published at
- by gurufocus.com
positivepositive- Published at
- by gurufocus.com
positivepositiveLynx1 Capital Management LP Increases Stake in Passage Bio Inc
On December 27, 2024, Lynx1 Capital Management LP (Trades, Portfolio) made a significant move by acquiring an additional 373,645 shares of Passage Bio Inc (PASG- Published at
- by gurufocus.com
positivepositiveSkorpios Trust Reduces Stake in Stoke Therapeutics Inc
On December 23, 2024, Skorpios Trust (Trades, Portfolio) executed a significant transaction involving Stoke Therapeutics Inc (NASDAQ: STOK). The firm reduced it- Published at
- by zacks.com
neutralneutralThe Zacks Analyst Blog Highlights ADMA Biologics, Tarsus Pharmaceuticals, Stoke Therapeutics, Inc. and ChromaDex
ADMA Biologics, Tarsus Pharmaceuticals, Stoke Therapeutics, Inc. and ChromaDex are part of the Zacks top Analyst Blog.- Published at
- by investing.com
positivepositiveStoke therapeutics' general counsel sells $123,890 in stock By Investing.com
Stoke therapeutics' general counsel sells $123,890 in stock- Published at
- by investing.com
positivepositiveStoke Therapeutics chief medical officer Ticho sells $178,182 in stock By Investing.com
Stoke Therapeutics chief medical officer Ticho sells $178,182 in stock- Published at
- by gurufocus.com
positivepositive- Published at
- by gurufocus.com
positivepositiveGeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced Biogen (Nasdaq: BIIB), Praxis Precision Medicin- Published at
- by investing.com
positivepositiveGeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners By Investing.com
GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners- Published at
- by benzinga.com
mixedmixedPure Storage Posts Upbeat Results, Joins Cross Country Healthcare, Marvell Technology, Stoke Therapeutics And Other Big Stocks Moving Higher On Wednesday - Altimmune (NASDAQ:ALT), Bitdeer Technologies
U.S. stocks were higher, with the Dow Jones index gaining more than 150 points on Wednesday. Shares of Pure Storage Inc PSTG gained 26.1% to $67.48 after the c...